Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Emerg Infect Dis ; 30(5): 1053-1055, 2024 May.
Article in English | MEDLINE | ID: mdl-38666748

ABSTRACT

We describe a feline sporotrichosis cluster and zoonotic transmission between one of the affected cats and a technician at a veterinary clinic in Kansas, USA. Increased awareness of sporotrichosis and the potential for zoonotic transmission could help veterinary professionals manage feline cases and take precautions to prevent human acquisition.


Subject(s)
Cat Diseases , Sporotrichosis , Zoonoses , Animals , Cats , Female , Humans , Animal Technicians , Cat Diseases/microbiology , Cat Diseases/epidemiology , Cat Diseases/transmission , Kansas/epidemiology , Sporothrix/isolation & purification , Sporothrix/genetics , Sporotrichosis/veterinary , Sporotrichosis/transmission , Sporotrichosis/epidemiology , Sporotrichosis/microbiology , Zoonoses/epidemiology , Zoonoses/microbiology , Zoonoses/transmission
2.
MMWR Morb Mortal Wkly Rep ; 73(11): 239-244, 2024 Mar 21.
Article in English | MEDLINE | ID: mdl-38512795

ABSTRACT

Coccidioidomycosis, histoplasmosis, and blastomycosis are lower respiratory tract fungal infections whose signs and symptoms can resemble those of other respiratory illnesses, including pneumonia caused by bacterial or viral etiologies; this overlap in clinical presentation might lead to missed or delayed diagnoses. The causative fungi live in the environment, often in soil or plant matter. To describe the epidemiologic characteristics of cases of coccidioidomycosis, histoplasmosis, and blastomycosis during the COVID-19 pandemic, CDC analyzed case surveillance data for 2019-2021. During this period, a total of 59,655 coccidioidomycosis cases, 3,595 histoplasmosis cases, and 719 blastomycosis cases were reported to CDC. In 2020, fewer cases of each disease occurred in spring compared with other seasons, and most cases occurred in fall; national seasonality is not typically observed, and cases were seasonally distributed more evenly in 2019 and 2021. Fewer cases coinciding with the start of the COVID-19 pandemic, along with an unusually high blastomycosis case fatality rate in 2021 (17% compared with more typical rates of 8%-10%), suggest that the pandemic might have affected patients' health care-seeking behavior, public health reporting practices, or clinical management of these diseases. Increased awareness and education are needed to encourage health care providers to consider fungal diseases and to identify pneumonia of fungal etiology. Standardized diagnostic guidance and informational resources for fungal testing could be incorporated into broader respiratory disease awareness and preparedness efforts to improve early diagnosis of coccidioidomycosis, histoplasmosis, and blastomycosis.


Subject(s)
Blastomycosis , COVID-19 , Coccidioidomycosis , Histoplasmosis , Respiratory Tract Infections , Humans , United States/epidemiology , Blastomycosis/epidemiology , Histoplasmosis/diagnosis , Histoplasmosis/epidemiology , Histoplasmosis/microbiology , Coccidioidomycosis/diagnosis , Coccidioidomycosis/epidemiology , Pandemics , COVID-19/epidemiology , Respiratory Tract Infections/epidemiology
3.
mBio ; 15(2): e0308023, 2024 Feb 14.
Article in English | MEDLINE | ID: mdl-38193663

ABSTRACT

Candida auris is an emerging human fungal pathogen, first described in Japan in 2009, and first detected in the United States in 2016. Here, we report the first-ever description of C. auris colonizing a human pet, the first identification of C. auris in a non-human mammal in the United States and the first C. auris isolate from the state of Kansas. While analyzing the oral mycobiome of dogs from a shelter in Kansas, the oral swab from one dog was found to contain C. auris as well as three other fungal species. The presence of C. auris in a dog suggests the possibility of zoonotic transmission to humans. The isolate is a member of Clade IV, which has been found in patients in Chicago and Florida, while Clades I and III are the most prevalent in the United States. The isolate is resistant to fluconazole, terbinafine, and amphotericin B but susceptible to caspofungin, consistent with the drug-resistant characteristics of many human C. auris isolates. The source of C. auris transient colonization in this dog is unknown, and there is no evidence that it was further transmitted to humans, other dogs in the shelter, or pets in its adopted household. Isolation of C. auris from a dog in Kansas has public health implications as a potential emerging source for the zoonotic spread of this pathogenic fungus, and for the development of antifungal resistance.IMPORTANCECandida auris is an emerging fungal infection of humans and is particularly problematic because it is multi-drug resistant and difficult to treat. It is also known to be spread from person to person by contact and can remain on surfaces for long periods of time. In this report, a dog in a shelter in Kansas is found to be colonized with Candida auris. This is the first study to document the presence of Candida auris on a pet, the first to document C. auris presence on a non-human mammal in the United States, and the first to report an isolate of C. auris within the state of Kansas. The presence of C. auris in a pet dog raises the possibility of zoonotic transmission from pets to human or vice versa.


Subject(s)
Antifungal Agents , Candidiasis , Dogs , Humans , Animals , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Candida , Candidiasis/microbiology , Candida auris , Kansas , Mouth , Mammals , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...